Clinically important upper GI bleeding · people admitted to intensive care units
Sucralfate probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Sucralfate showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
Sucralfate showed no clear difference in number of participants requiring blood transfusion compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (moderate to severe) compared with placebo/usual care; GRADE not reported.
1 finding from 1 review
RR 0.75 [0.54, 1.04]
4 studies
GRADE not reported
Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in mucositis eradicated compared with placebo; GRADE not reported.
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Sucralfate showed no clear difference in average pain scores (0-100 VAS) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Mean GI symptom scores · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).
1 finding from 1 review
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review